MetLife, Inc.

MetLife, Inc. (MET) Market Cap

MetLife, Inc. has a market capitalization of $50.71B.

Financials based on reported quarter end 2025-12-31

Price: $76.97

β–Ό -0.51 (-0.66%)

Market Cap: 50.71B

NYSE Β· time unavailable

CEO: Michel Abbas Khalaf

Sector: Financial Services

Industry: Insurance - Life

IPO Date: 2000-04-05

Website: https://www.metlife.com

MetLife, Inc. (MET) - Company Information

Market Cap: 50.71B Β· Sector: Financial Services

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.

Analyst Sentiment

75%
Strong Buy

Based on 33 ratings

Analyst 1Y Forecast: $96.56

Average target (based on 3 sources)

Consensus Price Target

Low

$90

Median

$97

High

$102

Average

$97

Potential Upside: 25.4%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ MetLife, Inc. (MET) β€” Investment Overview

🧩 Business Model Overview

MetLife, Inc. is a global provider of insurance, annuities, and employee benefit programs. Its core product and service lines include life insurance, dental, disability, accidental death insurance, and retirement solutions. The company caters to both individuals and institutional clients, serving businesses of all sizes with group benefits and retirement services, while also targeting consumers with personal protection solutions. Headquartered in the United States, MetLife operates across the Americas, Europe, Asia, and the Middle East, employing a large network of agents, brokers, and distribution partners to reach its broad and diverse customer base.

πŸ’° Revenue Model & Ecosystem

MetLife generates revenue through diversified streams across its global ecosystem. Primary income arises from insurance premiums collected on individual and group policies, as well as fees and spread income related to annuities and asset management. The group benefits segment supports enterprise clients via employee benefit packages, while retail solutions offer direct-to-consumer products. Beyond traditional insurance, MetLife earns investment income from its extensive portfolio, which includes fixed-income securities and alternative assets, reflecting the float-centric nature of the insurance industry. These models combine recurring revenue from long-term contracts with additional upside from investment activities, generating a balanced, multi-layered financial profile.

🧠 Competitive Advantages

  • Brand strength
  • Switching costs
  • Ecosystem stickiness
  • Scale + supply chain leverage

πŸš€ Growth Drivers Ahead

Several strategic and long-term tailwinds support MetLife’s growth trajectory. Demographic trends such as aging populations drive demand for life insurance and retirement solutions globally. Expansion into underpenetrated international markets adds potential for new business across emerging economies. MetLife is also intensifying its focus on digital transformation, automating back-office operations and enhancing the customer experience through digital channels, which is expected to both improve efficiency and drive retention. In the institutional space, increased corporate demand for employee benefits packages and retirement planning services provides scalable revenue opportunities. Partnerships, innovation in new financial protection solutions, and prudent integration of insurtech capabilities represent further strategic growth levers.

⚠ Risk Factors to Monitor

Key risks for MetLife include sustained competition from both established insurers and digital-first disruptors, which could compress margins or erode market share. Regulatory regimes remain complex and can shift unpredictably, impacting capital requirements and product design. Prolonged periods of low interest rates may pressure investment margins and profitability of insurance float. Additionally, shifts in consumer preferences toward more flexible, digital offerings could challenge legacy distribution and service models. Cybersecurity threats and operational risks, especially amid digital transitions, add further operational complexity.

πŸ“Š Valuation Perspective

The market tends to value MetLife in relation to other global multiline insurers, considering a mix of growth potential, balance sheet strength, and capital return policies. Typically, MetLife’s valuation stands at either a discount or a premium to peers depending on investor confidence in its risk management, efficiency of operations, and scale advantages. Market sentiment often considers the company’s resilience to macroeconomic and regulatory cycles, its dividend and capital return policy, as well as execution in expanding digital and international segments.

πŸ” Investment Takeaway

MetLife, Inc. stands as a well-established insurance leader with global scale, a diversified revenue structure, and significant brand equity. On the bullish side, the company benefits from secular demand in life and retirement products, ongoing digital transformation, and international expansion. On the bearish side, it faces significant competition, interest rate and regulatory uncertainties, and the operational challenge of modernizing traditional insurance models. Investors should weigh MetLife’s strong franchise and adaptability against industry headwinds and the evolving landscape of financial services.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"MET’s latest quarter (2025-12-31) reported Revenue of $23.81B and EPS of $1.17. On a QoQ basis, Revenue rose sharply (+41.1% from 2025-09-30), but Net Income fell to $0.81B (-9.7% QoQ; EPS -4.9%). YoY, Revenue grew strongly (+29.1% vs. 2024-12-31) while Net Income declined materially (-36.3%; EPS -34.6%), indicating profitability pressure despite top-line strength. Net margin contracted from ~5.3% (2025-09-30) to ~3.4% (2025-12-31), and compared with ~6.9% a year agoβ€”so profitability is deteriorating over the 4-quarter window. Balance sheet metrics look stable for an insurer: Total Assets increased to $745.2B (+3.5% QoQ; +10.0% YoY) while Total Equity was roughly flat ($28.9B, slightly down QoQ). Net debt improved materially (more negative) to -$1.85B from -$0.40B QoQ, suggesting better net liquidity positioning. Shareholder returns have been modest: the stock is up only +8.9% over 1 year and the dividend yield is ~0.77%, with a payout ratio around ~50% (less conservative than prior year). Analysts’ consensus target (~$96.5) implies ~24% upside from $78.08."

Revenue Growth

Good

Revenue accelerated sharply QoQ (+41.1% from $16.88B to $23.81B) and was up strongly YoY (+29.1% vs. $18.44B). Trend is positive on the top line, though profitability is not keeping pace.

Profitability

Neutral

Net Income declined QoQ (-9.7%) and YoY (-36.3%). Net margin contracted to ~3.4% from ~5.3% QoQ and ~6.9% YoY, showing meaningful margin pressure despite higher revenue.

Cash Flow Quality

Fair

Net Income is down YoY, which can pressure internal capital generation. Dividends are steady (yield ~0.77%) but payout ratio is ~50%, indicating moderate rather than highly conservative earnings coverage. Buybacks were not provided.

Leverage & Balance Sheet

Positive

Total Assets grew QoQ and YoY, while Total Equity was stable (~$27.7B to $29.2B range). Net debt improved to -$1.85B (more net cash) from -$0.40B QoQ, supporting resilience.

Shareholder Returns

Fair

1-year price gain is +8.9% (below the >20% momentum threshold). Dividend yield is low (~0.77%), and total return support is therefore modest. No buyback data included.

Analyst Sentiment & Valuation

Good

Consensus target of ~$96.5 vs. $78.08 current implies ~24% upside. Valuation appears reasonable (P/E ~16.2 on the provided ratio), though earnings trends weaken.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

MetLife delivered a record quarterly adjusted EPS ex-notables on broad-based segment strength, strong origination in PRT and UK longevity reinsurance, and continued momentum in Asia and Latin America. Capital deployment was robust with significant buybacks and dividends, liquidity remained solid, and operating efficiency improved aided by AI. While VII trailed the annual target and disability experience lagged, management’s outlook is confident, expecting continued favorable mortality, 2026 Group Benefits earnings growth, sustained demand in retirement risk transfer markets, and share repurchases in line with 2025, keeping the company on track to meet its five-year New Frontier commitments.

Growth

  • Q4 adjusted EPS ex-notables $2.58, up 24% y/y (highest single EPS quarter ex-notables)
  • Q4 adjusted PFOs up 8% to $12.8B; up 29% to $18.6B including retained PRT deals
  • Full-year 2025 adjusted EPS $8.89, up ~10% ex-notables; adjusted ROE 16%
  • Asia sales up 18% y/y (constant currency) for Q4 and full-year; GA AUM at amortized cost up 7% (CC)
  • Latin America Q4 adjusted earnings up 13% (4% CC); PFOs up 25% (CC); sales up 26% (CC)
  • EMEA Q4 adjusted earnings up 64%; PFOs up 21% (17% CC); sales up 24% (CC)
  • RIS Q4 adjusted earnings up 18%; full-year benefited from record origination
  • MIM AUM reached $742B at year-end, up from ~${600}B a year ago

Business Development

  • Closed acquisition of PineBridge Investments and created MetLife Investment Management (new business segment)
  • Seeded sidecar Chariot Re and entered US retail retirement via flow reinsurance
  • Originated record >$14B of PRT sales and ~$11B of UK longevity reinsurance (2025)
  • Executed strategic reinsurance: two Chariot deals (~$11B liabilities) and a Talcott risk transfer (~$10B liabilities)
  • Funded ~$1.2B of acquisitions/investments in 2025, including PineBridge, Mesero, and increased stake in PNB MetLife
  • Expanded LATAM digital platforms (e.g., Accelerator) and strengthened strategic partnerships
  • Repriced dental within Group Benefits back to target profitability
  • Adopted new reporting segmentation introducing MIM; revised adjusted earnings definition to exclude non-cash real estate depreciation

Financials

  • Q4 adjusted earnings $1.7B ex-notables; adjusted EPS $2.58 ex-notables
  • Q4 reported adjusted earnings $1.6B; EPS $2.49; notable items reduced EPS by $0.09 (Mexico VAT and higher asbestos reserves)
  • Q4 net income ~$800M; FY net income ~$3.2B
  • Variable investment income (VII) Q4 $497M; PE return 2.8% in Q4; real estate/other funds 1.1%
  • FY VII $1.5B (below $1.7B target), with PE full-year return 8.2% (vs 9% expected); real estate/other drove shortfall
  • Group Benefits Q4 adjusted earnings $465M (life mortality ratio 81.1% Q4; 83.1% FY; both below 84–89% target range); non-medical H&I adjusted benefit ratio 72.2%
  • RIS Q4 adjusted earnings $454M; investment spreads ex-VII 99 bps (up 1 bp seq); 2025 sales $42B (PRT >$14B; UK longevity $11B)
  • Asia Q4 adjusted earnings $444M; FY $1.6B; strong sales and expense margins, partly offset by less favorable underwriting vs PY
  • Latin America Q4 adjusted earnings $227M; strong volume and sales momentum
  • EMEA Q4 adjusted earnings $97M; robust volume and underwriting
  • MIM 2025 adjusted earnings $60M (vs $16M in 2024), aided by transition to general account market fees
  • Direct expense ratio 11.7% for 2025 (ahead of target); two-year average free cash flow ratio 81%
  • Accounting change (exclude non-cash real estate depreciation) added $57M to Q4 adjusted earnings; expected to add ~$200M annually (mostly corporate/other)

Capital & Funding

  • Deployed close to $4B in 2025 to support organic new business
  • Returned ~$2.9B via buybacks and ~$1.5B via dividends in 2025 (total ~$4.4B)
  • Retired ~$0.5B of debt in Q4; ended 2025 with $3.6B parent cash (within $3–4B target buffer)
  • Repurchased ~$430M of stock in Q4 and another ~$200M in January 2026; expect 2026 repurchases in line with 2025
  • Executed strategic reinsurance with Chariot (~$11B liabilities) and Talcott (~$10B liabilities) to enhance capital flexibility

Operations & Strategy

  • New Frontier strategy emphasizing responsible growth, disciplined capital deployment, and operating efficiency
  • AI and emerging technologies drove expense ratio improvements and operating leverage
  • Group Benefits growth led by voluntary products (voluntary PFOs +10% y/y) and scale/technology advantages
  • Focus on convergence of life insurance and asset management through MIM expansion
  • Strengthened retirement platform via sidecar/reinsurance structures and record PRT/longevity origination
  • International growth focus: product innovation (FX-denominated in Japan/Korea) and digital distribution in LATAM

Market & Outlook

  • On track to meet five-year commitments: double-digit adjusted EPS growth, 15–17% adjusted ROE, direct expense ratio path to ~11.3%, and $25B cumulative FCF
  • Expect favorable life mortality trends to persist in 2026
  • Group Benefits targeting 7–9% adjusted earnings growth in 2026, driven by PFO growth and underwriting
  • Sustained demand for PRT and UK longevity reinsurance; continued use of strategic reinsurance to support growth
  • 2026 share repurchases expected to be in line with 2025

Risks Or Headwinds

  • Disability experience below expectations (higher severity and incidence) despite being within pricing assumptions
  • VII below target and sensitive to private equity and real estate fund performance
  • Lower recurring interest margins partially offset overall growth
  • Derivative losses and FX impacts (strong USD) created volatility between net income and adjusted earnings
  • Regulatory and litigation items (Mexico VAT impact; higher asbestos reserves)
  • Macro and market uncertainty (rates, equity markets) may affect investment income and hedging results

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the MET Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (MET)

Β© 2026 Stock Market Info β€” MetLife, Inc. (MET) Financial Profile